Table 1.
Demographic and treatment characteristics of SLE patients included in the whole genome wide DNAm study
| AA | EA | |||
|---|---|---|---|---|
| Demographic and treatment characteristic | LN− (n=14) | LN+ (n=16) | LN− (n=12) | LN+ (n=6) |
| Age, median (IQR) years | 46.5 (35, 56.5) | 36.5 (31.5, 47.2) | 54 (46, 59) | 40 (38, 55) |
| Smoking History, n (%) | ||||
| Ever | 3 (21.4%) | 0 (0%) | 1 (8.3%) | 1 (16.7%) |
| Never | 11 (78.6%) | 16 (100%) | 11 (91.7%) | 5 (83%) |
| Disease Duration, median (IQR) years | 6.1 (3.2, 8.3) | 8.6 (3.9, 13.7) | 6.0 (3.1, 13.0) | 2.4 (1.7, 4.9) |
| Histologic Subtype for LN, n (%) | ||||
| II | 0 (0%) | 2 (12.5%) | 0 (0%) | 0 (0%) |
| III | 0 (0%) | 4 (25%) | 0 (0%) | 2 (33.3%) |
| IV | 0 (0%) | 1 (6.25%) | 0 (0%) | 2 (33.3%) |
| V | 0 (0%) | 9 (56.2%) | 0 (0%) | 2 (33.3%) |
| SLEDAI, median (IQR) | 2.0 (0.0, 6.3) | 2.5 (0.0, 6.3) | 2.0 (0.0, 4.0) | 2.0 (0.5, 3.5) |
| SDI, median (IQR) | 0.5 (0.0, 1.0) | 1.5 (0.00, 3.3) | 0.0 (0.0, 0.0) | 0.50 (0.0, 1.0) |
| Hydroxychloroquine, n (%) | 12 (85.7%) | 15 (93.8%) | 9 (75%) | 2 (33%) |
| Systemic Glucocorticoids, n (%) | 7 (50%) | 6 (37.5%) | 4 (33%) | 3 (50%) |
| Immunosuppressants, n (%) | 7 (50%) | 9 (56.2%) | 4 (33%) | 4 (67%) |
| Methotrexate | 4 (28.6%) | 3 (18.8%) | 4 (33%) | 0 (0%) |
| Mycophenolate | 3 (21.4%) | 5 (31.3%) | 0 (0%) | 3 (50%) |
| Belimumab | 1 (7.1%) | 1 (6.3%) | 3 (25%) | 2 (33%) |
AA: African American; EA: European American; LN: lupus nephritis; SLEDAI: systemic lupus erythematosus disease activity index; SLICC-DI: Systemic Lupus International Collaborating Clinics Damage Index; IQR: interquartile range; LN: Lupus Nephritis